Competitor Analysis - Rabies Virus Vaccines, Antibodies and Immune Globulins, New Report Launched

The present Competitive Intelligence Report about prophylaxis and therapy of Rabies virus infections provides a competitor evaluation in the field of marketed and new molecules for prevention or treatment of Rabies virus infections as of September 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently marketed and active projects in research and development of therapeutic antibodies, immune globulins and vaccines for prevention and treatment of Rabies virus infections. In addition, the report lists company-specific R&D pipelines of Rabies virus vaccines, antibodies and immune globulins. Competitor projects are listed in a tabular format providing information on:

• Drug Codes
• Target / Mechanism of Action
• Class of Compound
• Company
• Product Category
• Indication
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Spanning over 33 pages, “Competitor Analysis: Rabies Virus Vaccines, Antibodies and Immune Globulins” report covering the Equine Rabies Virus Immune Globulins (ERIG), Human Rabies Virus Immune Globulins (HRIG), Recombinant Rabies Antibodies, Rabies Virus Vaccines

Know more about this report at – http://mrr.cm/ZjK